Stimulation of host anti-tumor immune response

Stimulation of host anti-tumor immune response refers to the enhancement of the body’s own immune mechanisms to recognize and destroy cancer cells. This response involves both innate (e.g., dendritic cells, natural killer cells) and adaptive (T cell-mediated) immunity, with processes such as antigen presentation, type I interferon production, and activation of cytotoxic T lymphocytes playing central roles[1][2][3][4][5]. Therapeutic strategies aim to boost these responses using immune checkpoint inhibitors, cytokines, and pathway agonists, but face challenges due to tumor- and host-mediated immune suppression within the tumor microenvironment as well as the risk of systemic immune-related toxicities[1][2][3][4][5].

Other names

Stimulation of antitumor immunityActivation of host antitumor immune responseEnhancement of immune response to tumors

Mechanism of action involves multiple pathways aimed at enhancing the immune response against tumors, including activation of cytotoxic T lymphocytes against tumor antigens, stimulation of innate immune sensors such as STING pathway, enhancement of antigen presentation by dendritic cells, and blockade of immune checkpoints to restore T cell activity.